Last updated: June 15, 2026
Amgen Inc. v. MSN Laboratories Private Limited (1:21-cv-00712): Litigation Summary, Patent Claims, and Generic-Entry Implications
Amgen Inc. v. MSN Laboratories Private Limited, No. 1:21-cv-00712 (D. Del.) is an ANDA patent-infringement case tied to a Paragraph IV certification and Amgen’s asserted patent estate for an Amgen-branded small-molecule drug. The case posture and near-term generic-entry risk turn on (i) which asserted Orange Book patents were listed and challenged, (ii) the court’s claim-construction and dispositive rulings (summary judgment, preliminary injunction posture, or dismissal), and (iii) whether the matter ended in a settlement that triggers FDA forfeiture protections under the Hatch-Waxman framework.
What is the case background in Amgen Inc. v. MSN Laboratories Private Limited (1:21-cv-00712)?
Case caption: Amgen Inc. v. MSN Laboratories Private Limited
Docket: 1:21-cv-00712
Court: U.S. District Court for the District of Delaware (federal Hatch-Waxman venue)
Core legal theory (typical for this docket type): Patent infringement under 35 U.S.C. § 271(e)(2) based on an ANDA submission containing a Paragraph IV certification to an Orange Book listed patent.
Business relevance: These cases are designed to block FDA approval until the asserted patent expires or is held invalid or not infringed, and to convert generic launch timing into a settlement-driven schedule.
What patents were asserted in the complaint?
Not provided in the input. Without the specific asserted patent numbers and claim groupings from the complaint or infringement contentions, a complete infringement/validity analysis cannot be produced.
What is the ANDA context and Paragraph IV posture?
Not provided in the input. A litigation-grade summary requires the ANDA applicant, the FDA application number, the drug strength/dosage forms, and the Paragraph IV certification’s specific Orange Book patents.
Which patents protect Amgen’s drug in this dispute, and how broad is the estate?
Not provided in the input. A patent-estate strength analysis requires:
- asserted patent list (publication and/or U.S. numbers)
- expiration dates (including PTA and PTE if applicable)
- claim types (composition, formulation, method-of-use, manufacturing)
- whether the asserted claims are dependent on specific embodiments that constrain design-arounds
Composition vs. method-of-use vs. formulation: what matters for design-around risk?
- Composition-of-matter patents usually produce the highest barrier to generic launch because design-arounds often still fall within the chemical scope.
- Method-of-use patents can be navigated by labeling carve-outs, at least in some contexts, but require careful FDA labeling strategy and physician-facing use constraints.
- Formulation or process patents can sometimes be avoided through alternative manufacturing or different formulation, but only if the claims are not written broadly or if the court does not apply equivalents aggressively.
What does the litigation timeline show for claim construction, injunctions, and dispositive rulings?
Not provided in the input. A complete litigation timeline requires docket events, including:
- initial complaint filing date
- answer and counterclaims
- Markman/claim-construction schedule
- summary judgment motions
- Daubert/expert decisions if any
- preliminary injunction or stay status if pursued
- final judgment or dismissal basis
How do court decisions affect generic launch timing?
In Hatch-Waxman cases, generic timelines shift primarily through:
- Claim construction narrowing or broadening infringement scope
- Validity rulings (anticipation/obviousness) that can accelerate design-around or invalidation
- Injunction status (if any) that can delay FDA approval even if FDA is ready to act
What settlement or dismissal outcomes occurred in Amgen v. MSN Laboratories (1:21-cv-00712)?
Not provided in the input. Settlement vs. judgment drives the practical outcome:
- Settlement commonly includes an agreed launch date, licensing, and design-around terms.
- Judgment after trial can lead to immediate launch if claims are held invalid or not infringed.
- Dismissal can be procedural (e.g., stipulation) and may still carry an agreed commercial schedule.
How does a settlement affect Paragraph IV forfeiture exposure?
Settlement can trigger two-track implications:
- Agreement-based launch timing
- Regulatory consequences under 21 U.S.C. § 355(j) tied to the 30-month stay and FDA approval triggers
Without the docket outcome, no credible forfeiture or launch inference can be produced.
What is the Orange Book status of the asserted patents, and which listings drove the Paragraph IV?
Not provided in the input. For an Orange Book-driven summary, the analysis must identify:
- the NDA/ANDA link (NDA number and listed drug)
- the exact Orange Book patent numbers litigated
- listed exclusivities (3-year, 5-year, or other), if any
- whether the patents are “listed” or later withdrawn
How does this case compare with other Amgen v. generic-company litigations?
Not provided in the input. Comparative strength depends on:
- whether Amgen’s asserted patents in this matter are similar to its other estates (same active ingredient class or delivery/formulation)
- whether courts in prior matters construed the same claim language consistently
- whether Amgen’s infringement theory is method-dependent or composition-dependent
Commercial and R&D impact: what generic-entry risks exist for MSN Laboratories and for other ANDA filers?
Not provided in the input. Generic-entry risk requires:
- what the ANDA intended launch product is (strength and dosage form)
- whether the case involves a “first-filer” or a later-filer ANDA
- whether other ANDAs are at risk of being blocked by the same patents (shared Orange Book estate)
What product-design constraints typically arise from Amgen’s asserted patent families?
- If the patents are composition claims, a generic must either fall outside the chemical scope or secure invalidity/non-infringement.
- If the patents are method-of-use claims, labeling strategy and induced infringement risk become central.
- If the patents are formulation/manufacturing claims, process validation and design-around manufacturing records become central.
Key takeaways
- The docket number indicates a Hatch-Waxman ANDA Paragraph IV litigation in Delaware, but the input does not include the asserted patent numbers, claim categories, or docket events needed for a litigation-grade summary.
- A credible analysis of infringement scope, validity risks, claim-construction outcomes, and launch-date consequences cannot be completed from the information provided.
- The practical result for generic entry depends on final judgment or settlement terms tied to the specific Orange Book patents and exclusivity windows, which are not included in the input.
FAQs
- What does a Delaware Hatch-Waxman case number like 1:21-cv-00712 typically indicate about the filing date and ANDA posture?
- How do Paragraph IV certifications map to Orange Book patent numbers and drive §271(e)(2) liability?
- What court events most directly change generic approval timelines in Amgen-style patent cases?
- How do settlements in ANDA patent litigation generally allocate launch dates and design-around boundaries?
- What claim types (composition, method-of-use, formulation) create the highest generic design-around risk?
References
(No sources were provided in the input.)
